AX-024

• Description:

  AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 modulates cell signaling by targeting SH3 domains. AX-024 has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  IFNAR; Interleukin Related; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/AX-024.html

• Purity:

  99.73

• Solubility:

  DMSO : 35 mg/mL (ultrasonic; warming) |Ethanol : 100 mg/mL (ultrasonic)

• Smiles:

  COC1=CC=C(OC2)C(C(C3=CC=C(F)C=C3)=C2CN4CCCC4)=C1

• Molecular Formula:

  C21H22FNO2

• Molecular Weight:

  339.40

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Borroto A, et al. First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Sci Transl Med. 2016 Dec 21;8 (370) :370ra184.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  IL-10; IL-17; IL-6; TNFRSF5/CD40

• CAS Number:

  [1370544-73-2]